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Abstract
Background: In a previous study, progesterone treatment of female monkeys immunized with live, attenuated SHIV89.6
abrogated the generally consistent protection from vaginal simian immunodeficiency virus (SIV) challenge. The mechanisms
responsible for the loss of protection remain to be defined. The objective of the present study was to determine whether
Depo-ProveraH administration alters protection from intravenous SIV challenge in SHIV-immunized female macaques.
Methods and Findings: Two groups of female macaques were immunized with attenuated SHIV89.6 and then challenged
intravenously with SIVmac239. Four weeks before challenge, one animal group was treated with Depo-ProveraH, a
commonly used injectable contraceptive progestin. As expected, SHIV-immunized monkeys had significantly lower peak
and set-point plasma viral RNA levels compared to naı¨ve controls, but in contrast to previously published findings with
vaginal SIV challenge, the Depo-ProveraH SHIV-immunized animals controlled SIV replication to a similar, or even slightly
greater, degree than did the untreated SHIV-immunized animals. Control of viral replication from week 4 to week 20 after
challenge was more consistent in the progesterone-treated, SHIV-immunized animals than in untreated, SHIV-immunized
animals. Although levels of interferon-c production were similar, the SIV-specific CD8+ T cells of progesterone-treated
animals expressed more functions than the anti-viral CD8+ T cells from untreated animals.
Conclusions: Depo-ProveraH did not diminish the control of viral replication after intravenous SIV challenge in female
macaques immunized with a live-attenuated lentivirus. This result contrasts with the previously reported effect of Depo-
ProveraH on protection from vaginal SIV challenge and strongly implies that the decreased protection from vaginal
challenge is due to effects of progesterone on the genital tract rather than to systemic effects. Further, these results
demonstrate that the effects of hormonal contraceptives on vaccine efficacy need to be considered in the context of testing
and use of an AIDS vaccine.
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Introduction
In the simian immunodeficiency virus (SIV) model of AIDS,
only live-attenuated viruses consistently confer reliable protection
against intravaginal virus inoculation [1,2]. Immunizing rhesus
macaques with attenuated simian/human immunodeficiency virus
(SHIV) 89.6 protects 60% of the animals from uncontrolled
SIVmac239 virus replication and progression to AIDS after
intravaginal challenge [1–3]. However, treatment with progester-
one prior to SIV challenge dramatically decreases the efficacy of
this live-attenuated vaccine strategy [4]. Although SHIV 89.6
infection is persistant in the immunized animals, in this model
vaccine failure is due to uncontrolled SIV replication and not due
to replication of the vaccine virus [3]. Elucidating the mechanisms
by which progesterone decreases attenuated SHIV-mediated
protection from vaginal SIV challenge may provide insight into
the immune mechanisms involved in protection in this model.
Because HIV infection affects mainly women of reproductive
age, it is important to consider the impact of hormonal
contraception on HIV transmission and progression of HIV
infection [5–8]. Moreover, Depo-ProveraH, a contraceptive
progestin, is used in the SIV/macaque vaginal transmission model
to synchronize menstrual cycles and increase SIV transmission
efficiency [9], a strategy that may affect the results of SIV vaccine
experiments [10]. Administration of Depo-ProveraH to macaques
in the commonly used dosage, 30 mg, leads to epithelial thinning
[9], but genital tract epithelial thinning has not been found in
women using this contraceptive at a lower dose [10,11]. Thus, it is
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unclear if this mechanism of enhancing susceptibility to SIV
infection is relevant to women.
In addition to thinning the vaginal mucosal of rhesus macaques,
sex steroid hormones have many complex and undefined effects on
the immune system that might modify S/HIV transmission and
affect disease progression [10]. Progesterone induces cell-mediated
immunosupression, which may help to maintain a successful
pregnancy [10,12–16]. Progesterone increases the recruitment of
inflammatory cells into the genital mucosa, which could potentially
promote HIV-1 transmission [17]. Conversely, progesterone can
reduce pro-inflammatory cytokine and chemokine production
[18–20]. Which, if any, of these effects contribute to the decreased
protection from vaginal SIV challenge in SHIV-immunized rhesus
macaques treated with Depo-ProveraH is unknown.
The objective of the present study was to determine if SHIV-
immunized female rhesus macaques treated with Depo-ProveraH
are protected after intravenous (IV) SIV challenge. We reasoned
that if the levels of protection from IV and vaginal SIV challenge
are equivalent in SHIV-immunized macaques treated with Depo-
ProveraH, then systemic, rather than vaginal mucosal, effects of
progesterone account for the reduced protection from vaginal SIV
challenge after Depo-ProveraH treatment [4]. We found that
treatment with Depo-ProveraH did not decrease vaccine efficacy
compared to untreated, SHIV-immunized animals, and unex-
pectedly, it may have increased the proportion of animals within
the Depo-ProveraH- treated group that control viral replication.
After peak viremia, the difference in plasma viral RNA (vRNA)
levels between the Depo-ProveraH-treated group and the unim-
munized, control group was more significant than the difference in
the plasma vRNA levels between the untreated, SHIV-immunized
animals and the unimmunized group (p,0.01 vs p,0.05).
Vaccine-mediated protection in the Depo-ProveraH SHIV-immu-
nized animals was associated with an increased number of SIV
specific-CD8+ T cells within an environment of regulated immune
activation.
Methods
Animals
Multiparous, normally cycling female rhesus macaques (Macaca
mulatta) were housed at the California National Primate Research
Center in accordance with the regulations of the American
Association for Accreditation of Laboratory Animal Care
standards. The experiments were approved by the Institutional
Animal Care and Use Committee of the University of California,
Davis. All animals were negative for antibodies to HIV-2, SIV,
simian type-D retrovirus, and simian T cell lymphotropic virus
type1 at the time the study was initiated. To minimize discomfort,
animals were anesthetized with ketamine hydrochloride (10 mg/
Kg; Parke-Davis, Morris Plains, NJ) or 0.7 mg/kg tiletamine HCl
Figure 1. Plasma vRNA levels after IV challenge with SIVmac239. (A) unimmunized macaques, (B) SHIV-immunized macaques and (C)
progesterone-treated, SHIV-immunized macaques. In panel (D), cumulative vRNA levels over the 20 weeks of observation were transformed into areas
under the curve (AUC) and the median AUC of the 3 groups of animals were compared. The Kruskal-Wallis test and a pair-wise comparison between
the 2 groups of immunized animals and the unimmunized group using Dunn’s multiple comparisons test were performed.
doi:10.1371/journal.pone.0009814.g001
Progesterone and AIDS Vaccine
PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9814
and zolazepan (Telazol, Fort Dodge Animal Health, Fort Dodge,
IA) injected intramuscularly for all procedures.
SHIV89.6 immunization, Depo-ProveraH treatment and
SIV challenge
Eleven macaques were immunized by IV inoculation with live,
attenuated SHIV89.6 [1]. Six months after SHIV 89.6 inocula-
tion, and 4 weeks before challenge with SIV, a single 30 mg dose
of Depo-ProveraH [4] was administered by intramuscular injection
to 6 randomly selected macaques. Hereafter, these 6 macaques are
referred as ‘‘Depo-ProveraH SHIV macaques’’ and the 5
untreated, SHIV-immunized macaques are referred as ‘‘SHIV
macaques’’. Seven unvaccinated control macaques referred as
‘‘naı¨ve controls’’ were challenged IV with SIVmac239 contempo-
raneously with the 11 SHIV-immunized macaques. A stock of
pathogenic SIVmac239 was used as previously described [2] and
contained approximately 105 TCID50/ml. All of the animals were
given a single IV inoculation containing 103 TCID50 of the
SIVmac239 stock in 1 ml of sterile saline. Approximately, five
months after IV SIVmac239 challenge, all the monkeys were
necropsied and blood and tissues were collected.
PBMC Isolation
Peripheral blood mononuclear cells (PBMC) were isolated as
described [2].
RNA isolation and cytokine mRNA levels
Total RNA was isolated with Trizol (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions from cryopreserved
PBMC samples. RNA samples were DNase treated with DNA-free
(Ambion) for 1 h at 37uC. cDNA was prepared using random
hexamer primers (Amersham-Pharmacia Biotech, Inc., Piscat-
away, NJ) and superscript III reverse transcriptase (Invitrogen).
Cytokine mRNA levels were determined by real-time PCR as
described previously [1].
Plasma vRNA Measurement
Plasma samples were analyzed for vRNA by a quantitative
branched DNA assay as previously described [2]. Viral titers in
plasma samples are reported as vRNA copy numbers per ml of
plasma. The quantitation limit of this assay was 125 vRNA copies/
ml plasma.
Figure 2. Changes in peripheral CD4+ T cell populations after IV SIVmac239 challenge. (A) Number of CD4+ T cells, and (B) the percentage
of CD4+ CD95+ T cells in blood. (l) Naı¨ve control macaques (n = 7), (#) SHIV-immunized macaques (n = 5) and (5) Depo-ProveraH SHIV-immunized
macaques (n = 6). The number of CD4+ T cells (p = 0.0007) and the percentages of CD4+ CD95+ T cell (p,0.0001) were significantly higher (Friedman
test) in the Depo-ProveraH-treated, SHIV-immunized macaques than in the naı¨ve control group.
doi:10.1371/journal.pone.0009814.g002
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SIV-specific interferon-c ELISPOT Assay
The number of interferon (IFN)-c secreting cells in cryo-
preserved PBMC responding to a SIVmac239 Gag p27 peptide
pool was determined using a monkey-specific IFN-c ELISPOT kit
(U-CyTech, Utrecht University, Utrecht, Netherlands) as previ-
ously described [1,21].
SIV-specific T cell Proliferation Assay
Proliferation of PBMC in response to aldrithol-2-inactivated
SIVmac239 (provided by J. Lifson, SAIC Frederick, Bethesda,
MD) was measured by 3-H thymidine incorporation as previously
described [1,22]. A stimulation index (SI), calculated as the mean
counts per minute of replicate antigen wells divided by the mean
counts per minute of control wells, was scored positive if .2.0.
Flow cytometric analysis of cell populations in blood
The percentage of CD3+CD4+ and CD3+CD8+ T cells, natural
killer and CD20+ B cells, within the lymphocyte gate of PBMC
samples, was determined as described [21].
Intracellular cytokine staining of SIV-specific T cells
Cryopreserved PBMC were thawed, rested overnight and
stimulated with a p27 Gag-peptide pool at 5 mg/ml, or with
Gag epitope-peptides (CM9 or GY9) at 1 mg/ml, as described
[23]. Background controls contained co-stimulatory antibodies
and dimethyl sulfoxide, and a positive control was stimulated with
staphylococcal enterotoxin B. Intracellular staining for Ki67 and
caspase 3 was performed as described [23].
Figure 3. SIV-specific T cell responses after IV SIVmac239 challenge. (A) Mean number of SIV Gag p27 interferon (IFN)-c secreting cells in
PBMC before and after challenge. (B) Median area under the curve for the total IFN-c secreting cells in each group from week 2 to 16 PC, the time-
points for which samples were available. (C) Mean SIV-specific T cell proliferative responses in PBMC expressed as the stimulation index (SI) before
and after SIV challenge. See Methods for details. (D) Median area under the curve for the cumulative SI in each group from week -4 to 20 PC. (l) Naı¨ve
control macaques (n = 7), (#) SHIV-immunized macaques (n = 5) and (5) Depo-ProveraH SHIV-immunized macaques (n = 6). P values of a T test are
indicated.
doi:10.1371/journal.pone.0009814.g003
Progesterone and AIDS Vaccine
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Measurement of TNF-a and TGF-b in plasma
Tumor necrosis factor (TNF-a) and transforming growth factor
(TGF-b) levels in EDTA plasma samples were determined using
commercial ELISA kits according to the manufacturer’s instruc-
tions (QuantikineH, R&D Systems, Minneapolis, Minn.).
Statistical Analysis
The results of statistical analyses are reported as the mean and
the standard error of the mean for each group. Student’s t test was
performed for single time-point comparisons of Depo-ProveraH
treated SHIV-immunized and SHIV-immunized animals. The
non-parametric Friedman test for repeated measures, with Dunn’s
multiple comparisons post-hoc test, was used to analyze differences
among the three groups over the entire post-challenge period. To
determine if the cummulative levels of plasma vRNA, of
proliferative response or of spot-forming cells among the 3
monkey groups were significantly different over the post-challenge
phase, the median area under the curve (AUC) for each animal
TNFa
IL-2
IFNg
  SHIV              Depo-SHIV      SHIV               Depo-SHIV
0 wk
1 wk
2 wk
4 wk
  
   CM9 (*A01)             GY9  (*A02)
77   106          47   49
41a     121        ND    105
50   310          42   204
100   359    448    84
a
  Number of epitope-specific CD8+ T cells 
(per 105 CD3+ T cells)
1
2
3
 32454               30615                    30018              30615
Figure 4. Frequency and functional capacity of Gag CM9- and GY9-specific CD8+ T cells of SHIV-immunized animals after IV
SIVmac239 challenge. SIV-specific CD8+ T cell responses in cryopreserved PBMC from a Mamu-A*01 positive animal and a Mamu-A*02 positive
animal in each vaccinated group are shown as pie charts. The number of positive SIV-specific T cells normalized to 105 CD3+ T cells is shown for each
response as the white number in the center of the pie chart. Each portion of a pie chart indicates the percentage of SIV-specific T cells that responded
with one, two, or three functions; and the colored arcs around the pie show the cytokine or combination of cytokines comprising each response. ND
not done, as samples were not available.
doi:10.1371/journal.pone.0009814.g004
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group was computed and a Kruskal-Wallis test was applied. To
compare the median AUC between each monkey group, Dunn’s
multiple comparisons post-hoc test was used. The Spearman rank
correlation test was used to determine the correlation between
mRNA gene expression and viral load. All the above calculations
were done using Prism 4.0 software (Graph Pad Inc.) and a
Macintosh G5 computer (Apple Inc. Cupertino, CA). P values of
,0.05 were considered significant.
Results
Progesterone does not abrogate control of virus
replication and preserves CD4+ T cells after IV SIVmac239
challenge
Eleven female rhesus macaques were inoculated with SHIV89.6
and at 24 weeks after immunization (four weeks prior to IV
SIVmac239 challenge), Depo-ProveraH was administered to 6
randomly selected animals. Of note, there was no change in SHIV
plasma vRNA levels after treatment (Figure 1). At 1–2 weeks post-
challenge (PC), all 7 control animals had high peak plasma vRNA
levels of 107 vRNA copies/ml, which decreased to set point at 8–
12 weeks PC (Figure 1A). Nine of 11 SHIV89.6 immunized
animals had vRNA detected in plasma collected from 1–4 weeks
PC, and there was no difference between the two immunized
groups (p = 0.79, two-tailed unpaired T test; Figure 1B and C).
However, at 4 weeks PC, SHIV-immunized monkeys developed
very distinct patterns of viral replication. Animals defined as
‘‘protected’’ controlled viral replication (set point plasma vRNA
levels ,104 vRNA copies/ml) and had stable CD4+ T cells counts.
Animals defined as ‘‘unprotected’’ had plasma vRNA set point
levels.104 vRNA copies/ml and a decline in CD4+ T cells. Based
on these criteria, 100% (6/6) of the Depo-ProveraH SHIV
macaques were protected from uncontrolled virus replication
through 20 weeks PC. In contrast, only 40% (2/5) SHIV
macaques were protected from IV challenge with SIV. Although
in this study we did not distinguish which virus replicated in the
immunized macaques after challenge or whether recombination
occurred, a similar study using the same model has clearly shown
that only the challenge virus, SIVmac239, accounts for uncon-
trolled viral replication after challenge [3].
Using the plasma vRNA data for each animal, vRNA levels
over the entire post-challenge period were transformed into an
AUC value. The median plasma vRNA AUC for each of the 3
animal groups were significantly different (p = 0.002, Kruskal-
Wallis test) from one another (Figure 1D). While the SHIV
macaque group had a significantly lower (p,0.05, Dunn’s multiple
comparison post-hoc test) mean plasma vRNA AUC value than
the naı¨ve control group, the mean vRNA AUC value of the Depo-
ProveraH SHIV group was even lower compared to the naı¨ve
control group (p,0.01, Dunn’s multiple comparison post-hoc test)
(Figure 1D). These AUC analyses were further broken down to
distinguish peak and set point viremia. At peak viremia (0 to 4
week PC) both immunized groups had significantly lower viral
load compared to the naı¨ve control macaques (p = 0.0023 in
Kruskal-Wallis test, p,0.01 for both SHIV groups in Dunn’s
multiple comparison post-hoc test), but the two immunized groups
were not different from each other. Further, from week 8 to 20
PC, only the Depo-ProveraH SHIV monkeys had significantly
lower viral loads compared to naı¨ve control macaques (p = 0.0039,
data not shown).
The absolute number of CD4+ T cells in blood over the entire
post-SIV challenge time period differed among the 3 animal
groups (p = 0.0007, Friedman test, Figure 2A) as Depo-ProveraH
SHIV monkeys had significantly higher mean CD4+ T cells than
the naı¨ve control group (p,0.01; Figure 2A), while the SHIV
group did not. Additionally, after challenge, the frequency of
circulating memory CD95+ CD4+ T cells was significantly higher
in the Depo-ProveraH SHIV monkeys but not in the untreated
SHIV monkeys compared to the naı¨ve control group (p,0.0001,
Friedman test; Figure 2B). Thus, as observed for control of viral
replication, no differences in CD4+ T cell number were
Figure 5. Frequencies of activated T cells after progesterone
treatment and IV SIVmac239 challenge. A) Percent of CD3+ CD4+ T
cells expressing CD38 but not HLA-DR in PBMC. B) Percent of CD3+
CD8+ T cells expressing CD38 but not HLA-DR in PBMC. D) Percent of
CD3+ CD8+ T cells expressing Ki-67+ in PBMC. E) Percent of CD3+ CD8+ T
cells expressing caspase-3+ in PBMC. (#) SHIV-immunized macaques
(n = 5) and (5) Depo-ProveraH-treated, SHIV-immunized (n = 6).
doi:10.1371/journal.pone.0009814.g005
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attributable to progesterone treatment in these analyses. However,
when compared to naı¨ve control monkeys, Depo-ProveraH treated
macaques maintained significantly higher levels of memory and
total CD4+ T cells, while in the SHIV group, there was only a
trend.
SIV-specific T cell responses were stronger and more
polyfunctional in the Depo-ProveraH-treated, SHIV-
immunized than in the SHIV-immunized macaques after
SIV challenge
SIV-specific T cell proliferative responses and IFN-c spot
forming cells were assessed in PBMC samples (Figure 3). SIV
Gag-specific IFN-c ELISPOT responses were detected in the 2
SHIV-vaccinated groups from the day of progesterone treatment
until 16 week PC (Figure 3A), and when the IFN-c spot forming
cell counts for each animal, from week 2 to 16 PC, were
aggregated into an AUC value, a non-significant trend toward
higher responses in the progesterone-treated group was detected
(Figure 3B, p= 0.094, T test). After week 4 PC, SIV-specific T cell
proliferative responses were highest in the Depo-ProveraH SHIV
monkeys (Figure 3C) and only this group had significantly higher
T cell proliferative responses than the naı¨ve control group
overtime (p = 0.03, Friedman test). If each animal’s T cell
proliferative responses were aggregated to form an AUC, the
Depo-ProveraH SHIV group tended do have a higher cumulative
proliferative response compared to the SHIV group (Figure 3D,
p = 0.053, T test).
There were no significant differences in strength or pattern of
SIV p27-Gag specific CD8+ T cell responses in PBMC of the 2
SHIV-immunized groups as measured by intracellular cytokine
staining. However, in SHIV-immunized monkeys that were
MHC-typed as Mamu-A*01+ (one in each group) or Mamu-A*02+
(one in each group), the frequency of CD8+ T cells responding to
Figure 6. Frequencies of regulatory CD4+ T cells after progesterone treatment and IV SIVmac239 challenge. A) Percentages of CD4+
CD152+ T cells in PBMC. B) Percent of CD4+ FoxP3+ HLA-DR+ T cells after challenge in PBMC. C) Percentages of CD4+ CD152+ T cells in axillary LN of the
vaccinated animals at 12 weeks post-challenge. D) Percentages of CD4+ FoxP3+ HLA-DR+ T cells in axillary LN of the vaccinated animals at 12 weeks
post-challenge. (l) Naı¨ve control macaques (n = 7), (#) SHIV-immunized macaques (n = 5) and (5) Depo-ProveraH-treated, SHIV-immunized macaques
(n = 6).
doi:10.1371/journal.pone.0009814.g006
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immunodominant SIV Gag epitopes (CM9 for Mamu-A*01 or
GY9 for Mamu-A*02) was up to 6 times higher in the Depo-
ProveraH SHIV monkeys than in the SHIV monkeys during acute
infection (Figure 4). Further the SIV-specific T cell responses in
the Depo-ProveraH -treated animals were comprised of poly-
functional T cells, while the untreated, SHIV-immunized
macaques had mono-functional T cells secreting IFN-c or TNF-
a, with rare IL-2 secreting CD8+ T cells (Figure 4).
Depo-ProveraH treatment increased T cell activation and
apoptosis before SIV challenge but reduced T cell
proliferation and apoptosis after SIV challenge
There was a significant increase in frequency of HLA-
DR+CD38-CD4+ T cells in the lymph nodes (LN) of the Depo-
ProveraH SHIV monkeys between the day of progesterone
treatment and the day of SIV challenge (from a mean6SEM of
0.6260.04 to 1.2160.26; p = 0.032; Figure 5A). Further, the
frequencies of activated, caspase-3+ CD8+ T cells in PBMC
significantly increased between the day of treatment and the day of
challenge in the Depo-ProveraH SHIV monkeys (from 0.5660.1
to 4.562.5; p = 0.041; Figure 5B).
At 1 and 2 weeks PC, both SHIV-immunized groups had lower
frequencies of CD38+CD8+ T cells in PBMC (,55%) compared
to the naı¨ve control group (.70%, p,0.005 for the Depo-
ProveraH SHIV group, p,0.02 for the SHIV group; data not
shown). At 1 week PC, the HLA-DR+CD382 subsets of CD4+ and
CD8+ T cells in PBMC were significantly increased in both SHIV
groups compared to the naı¨ve control group (,1% vs ,0.5%,
p,0.05 in each subset from each group; data not shown). However
at 2 weeks PC, these HLA2DR+CD382 T cell subsets remained
significantly higher only in the Depo-ProveraH SHIV group
compared to the naı¨ve control group (p = 0.009 for CD8+ T cells
and p = 0.0001 for CD4+ T cells; data not shown).
Further, after challenge, the frequencies of Ki-67+ CD4+ T
cell in PBMC and axillary LN were similar in the two SHIV
immunized groups, although the frequency tended to be lower in
the Depo-ProveraH treated monkeys. By 12 weeks PC, there was
a significantly increased percentage of Ki-67+ CD8+ T cells in
the PBMC (1.660.2 vs 8.062.4; p = 0.018; Figure 5C) and
axillary LN (1.860.2 vs 3.561.0; p = 0.045) of the SHIV
macaques compared to the Depo-ProveraH SHIV macaques,
in which Ki-67+ CD8+ T cells remained at a low level. At 12
weeks PC, in the axillary LN of SHIV macaques there was a
significant increase in the frequency of caspase-3+ CD8+ T cells
compared to Depo-ProveraH treated monkeys (1.960.4 vs
5.261.1; p = 0.009). Finally, the frequency of Ki67+ caspase-3+
T cells in tissues of SHIV-immunized monkeys at 12 weeks PC
were very similar to the levels detected in naı¨ve controls and
significantly higher compared to the Depo-ProveraH SHIV
monkeys (p = 0.008 for CD8+ and p = 0.034 for CD4+ T cells;
data not shown). Thus, while progesterone treatment induced T
cell activation and turnover before and immediately after SIV
challenge, it was soon restricted. T cell activation, proliferation
and apoptosis was limited in the hormone-treated group after
challenge, while at 8–12 weeks PC the untreated monkeys with
high levels of viral replication had elevated levels of T cell
activation and turnover.
Increased regulatory T cell frequencies in Depo-ProveraH-
treated monkeys before and after SIV challenge
CD4+ regulatory T cells were counted by staining for CD25,
HLA-DR, CD152 and FoxP3. Both CD4+CD25+HLA-DR+ T
cells and CD4+Foxp3+HLA-DR+ T cell frequencies were
significantly higher on the day of challenge in the macaques
treated with Depo-ProveraH than in the untreated, SHIV-
immunized macaques (p = 0.047 and p = 0.0018 respectively, T
test, data not shown). Moreover, progesterone treatment increased
the frequency of circulating CD4+CD152+ T cells between the day
of treatment and the day of challenge (from 1.5% to 2.1%,
p = 0.08; Figure 6A). The frequency of CD4+CD152+ T cells was
low and very stable after challenge in all groups, except for week 2
PC, when this subset increased in both SHIV-immunized groups
(Figure 6A): however, this increase was significant only for the
Depo-ProveraH-treated group compared to the naı¨ve controls
(4.9% vs 2.3%, p = 0.045). Additionally, in LNs of the progester-
one-treated animals the frequency of CD4+CD152+ T cells tended
to be higher than in the untreated, SHIV-immunized animals at
12 wk PC (4.53% vs. 1.81%; p = 0.08; Figure 6B). There was also
higher frequency of CD4+Foxp3+ HLA-DR+ T cells in the LNs of
progesterone-treated animals compared to the untreated, SHIV-
vaccinated animals (p = 0.02, Figure 6C).
Depo-ProveraH treatment reduced inflammatory
responses after SIV challenge
After challenge, the Depo-SHIV and SHIV-immunized mon-
keys down-regulated TNF-a gene expression in PBMC compared
to levels on the day of challenge. At week 1 PC, this decrease in
TNF-a mRNA in both groups was highly significant (p = 0.0005
and p = 0.001 respectively, Figure 7A). Plasma TNF-a protein
levels were low and variable in all of the monkeys before SIV
challenge. However at 1 week PC, there were significantly lower
plasma TNF-a levels in the progesterone-treated animals
(2.160.6 pg/ml) compared to the untreated, SHIV group
(5.161.2 pg/ml; p = 0.05, T test).
In the Depo-ProveraH-treated, SHIV group TGF-b gene
expression was induced in PBMC (2-fold increase, p = 0.035) 4
weeks after SIVmac239 challenge and then returned to basal levels
rapidly (Figure 7B). TGF-b mRNA was also down regulated
immediately after challenge, but only in the SHIV-immunized and
the naı¨ve control groups (p = 0.0002 and p = 0.03 respectively,
Figure 7B). In fact, TGF-b mRNA levels were significantly higher
in the PBMC of the progesterone-treated animals compared to the
untreated, SHIV-immunized group at 1 week PC (p = 0.046;
Figure 7B), and compared to naı¨ve controls at 2 and 4 week PC
(p = 0.008 and p = 0.021; Figure 7B). Additionally, TGF-b mRNA
levels at 4 weeks PC negatively correlated with plasma vRNA
AUC levels from week 1 to 20 PC (r=20.51, P= 0.035, n = 17 x-y
pairs, Figure 7C). These results suggest that Depo-ProveraH
treatment blunted the pro-inflammatory response to SIV chal-
lenge and enhanced T regulatory-mediated suppression of
immune activation.
Discussion
In the present study we found that Depo-ProveraH did not blunt
or abrogate control of viral replication after IV SIV challenge of
SHIV-immunized female macaques. Thus, the abrogation of
vaccine-induced protection by treatment with Depo-ProveraH
before vaginal SIV challenge is not due to systemic, immunologic
effects of progestins. In addition, the possibly increased protection
in progesterone-treated, immunized monkeys against IV SIV
challenge is likely due to systemic effects of progestins on antiviral
immunity. In fact SHIV immunized female macaques treated with
Depo-ProveraH developed a stronger and more polyfunctional
CD8+ T cell response than untreated SHIV-immunized animals.
Moreover, IL-2 secretion was much more abundant in SIV-
specific CD8+ T cells from the Depo-ProveraH SHIV-immunized
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group than in the SHIV-immunized untreated group. Thus, as
previously suggested [24], the detection of circulating, SIV-specific
polyfunctional CD8+ T cells secreting IL-2 may indicate an
effective antiviral CD8+ T cell response. However, the route of
virus infection may influence the effect of Depo-ProveraH on
antiviral CD8+ T cells responses. In contrast to the results reported
here, we previously reported that, after vaginal SIV challenge,
SHIV-immunized rhesus macaques that were treated with Depo-
ProveraH have weaker CD8+ T cell responses and less control of
challenge virus replication than untreated, SHIV-immunized
animals [4]. Further, other labs have also shown that Depo-
ProveraH supresses cellular immunity in monkeys and mice
[13,14].
Depo-ProveraH treatment induced both transient T cell
activation and an increase in T regulatory cell frequency, changes
that may be critical for preventing aberrant immune activation
after challenge [25]. The lack of disease progression in SIV-
infected African green monkeys is associated with early expression
of TGF-b [26] that presumably contributes to minimal immune
activation and lack of disease progression in this natural host of
SIV. Thus, a critical factor in the lack of disease progression in
Depo-ProveraH SHIV animals may be control of early T cell
activation to avoid the aberrant immune activation that generally
develops soon after SIV infection of macaques or HIV infection of
humans [26,27]. In contrast to the effect on female rhesus
macaques, progesterone treatment decreased protection from IV
challenge with SIVmac239 in SHIV-immunized, male rhesus
macaques [21]. Although T cell activation was also enhanced in
progesterone-treated males [21], the anti-inflammatory response
that was found in females was not found in males. This gender-
dependent difference in the effect of Depo-ProveraH requires
further study.
In summary, Depo-ProveraH did not abrogate the control of
viral replication but it may have improved viral control after IV
challenge in SHIV-immunized female rhesus macaques. Depo-
ProveraH stimulated T cell activation and T regulatory responses
before and just after SIV challenge. Further, Depo-ProveraH
enhanced TGF-b expression and decreased TNF-a secretion after
challenge, establishing an anti-inflammatory environment in the
treated animals. These changes correlated with enhanced control
of challenge virus replication. Although it is possible that a direct
effect of progesterone on viral replication at the cellular level
contributed to the benefit observed, our findings clearly show that
exogenous progestins do not have a detrimental impact on
protection from IV challenge in female, SHIV-immunized
macaques. Further, the decreased protection from vaginal SIV
challenge in Depo-ProveraH treated, SHIV-immunized animals
must be due to local changes in the genital tract that enhance SIV
transmission, such as thinning of the vaginal epithelium [9] or
other immune effects limited to the female reproductive tract [10].
As hormonal contraceptive treatment is associated with disease
progression in HIV-infected, untreated women [7], there is a clear
and urgent need to understand how contraceptive compounds
modulate the immunological response in the context of HIV
infection and vaccination [8]. This study emphasizes the complex
impact of sex steroids on antiviral immunity and vaccine-mediated
protection from AIDS virus exposure.
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Figure 7. Cytokine mRNA levels after IV SIVmac239 challenge.
Changes in gene expression are shown as the fold-change relative to
the levels on the day of challenge for (A) TNF-a and (B) TGF-b. (C)
Spearman rank correlation of TGF-b at 4 weeks PC, for all animals, with
plasma viral RNA AUC between 1 and 20 weeks PC. (l) Naı¨ve control
macaques (n = 7), (#) SHIV-immunized macaques (n = 5) and (5) Depo-
ProveraH-treated, SHIV-immunized macaques (n = 6).
doi:10.1371/journal.pone.0009814.g007
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